Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Magnus Unemo

Showing results (421-430 of 438) with videos related to

Pageof 44
Sort By:
Genome Medicine|April 20, 2021
A community-driven resource for genomic epidemiology and antimicrobial resistance prediction of Neisseria gonorrhoeae at PathogenwatchLeonor Sánchez-Busó, Corin A Yeats, Benjamin Taylor, et al.
The Journal of Antimicrobial Chemotherapy|September 24, 2021
Antimicrobial susceptibility of Neisseria gonorrhoeae isolates and syndromic treatment of men with urethral discharge in Kingston, Jamaica, 2018-19Suzette M Cameron-McDermott, Geoffrey J Barrow, Alicia M Webster, et al.
Genome Research|March 26, 2013
Whole-genome sequences of Chlamydia trachomatis directly from clinical samples without cultureHelena M B Seth-Smith, Simon R Harris, Rachel J Skilton, et al.
The Journal of Antimicrobial Chemotherapy|March 18, 2025
Exceedingly high levels of tetracycline resistance in Neisseria gonorrhoeae in eight WHO Enhanced Gonococcal Antimicrobial Surveillance Programme countries in three WHO regions, 2021-2024-doxycycline post-exposure prophylaxis will unlikely impact gonorrhoea burdensDaniel Schröder, Thitima Cherdtrakulkiat, Le Huu Doanh, et al.
IJID Regions|April 21, 2025
High susceptibility to the novel antimicrobial zoliflodacin among <i>Neisseria gonorrhoeae</i> isolates in eight WHO Enhanced Gonococcal Antimicrobial Surveillance Programme countries in three WHO regions, 2021-2024Susanne Jacobsson, Thitima Cherdtrakulkiat, Daniel Golparian, et al.
Lancet (London, England)|December 14, 2025
Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trialAlison Luckey, Manica Balasegaram, Lindley A Barbee, et al.
The Lancet Regional Health. Western Pacific|September 9, 2025
Antimicrobial resistance in <i>Neisseria gonorrhoeae</i> in nine sentinel countries within the World Health Organization Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP), 2023: a retrospective observational studyIsmael Maatouk, Phiona Vumbugwa, Thitima Cherdtrakulkiat, et al.
Annals of the New York Academy of Sciences|August 10, 2011
The evolution of infectious agents in relation to sex in animals and humans: brief discussions of some individual organismsDavid L Reed, Russell W Currier, Shelley F Walton, et al.
Antimicrobial Agents and Chemotherapy|July 8, 2010
Multicenter study for defining the breakpoint for rifampin resistance in Neisseria meningitidis by rpoB sequencingMuhamed-Kheir Taha, Sara Thulin Hedberg, Marek Szatanik, et al.
The Journal of Antimicrobial Chemotherapy|December 16, 2025
High in vitro activity of the novel antimicrobial gepotidacin against Neisseria gonorrhoeae isolates in eight WHO Enhanced Gonococcal Antimicrobial Surveillance Programme countries in three WHO regions, 2021-24Josefine Ahlstrand, Ismael Maatouk, Le Huu Doanh, et al.
Pageof 44

Showing results (421-430 of 438) with videos related to

Sort By:
Pageof 44
Genome Medicine|April 20, 2021
A community-driven resource for genomic epidemiology and antimicrobial resistance prediction of Neisseria gonorrhoeae at PathogenwatchLeonor Sánchez-Busó, Corin A Yeats, Benjamin Taylor, et al.
The Journal of Antimicrobial Chemotherapy|September 24, 2021
Antimicrobial susceptibility of Neisseria gonorrhoeae isolates and syndromic treatment of men with urethral discharge in Kingston, Jamaica, 2018-19Suzette M Cameron-McDermott, Geoffrey J Barrow, Alicia M Webster, et al.
Genome Research|March 26, 2013
Whole-genome sequences of Chlamydia trachomatis directly from clinical samples without cultureHelena M B Seth-Smith, Simon R Harris, Rachel J Skilton, et al.
The Journal of Antimicrobial Chemotherapy|March 18, 2025
Exceedingly high levels of tetracycline resistance in Neisseria gonorrhoeae in eight WHO Enhanced Gonococcal Antimicrobial Surveillance Programme countries in three WHO regions, 2021-2024-doxycycline post-exposure prophylaxis will unlikely impact gonorrhoea burdensDaniel Schröder, Thitima Cherdtrakulkiat, Le Huu Doanh, et al.
IJID Regions|April 21, 2025
High susceptibility to the novel antimicrobial zoliflodacin among <i>Neisseria gonorrhoeae</i> isolates in eight WHO Enhanced Gonococcal Antimicrobial Surveillance Programme countries in three WHO regions, 2021-2024Susanne Jacobsson, Thitima Cherdtrakulkiat, Daniel Golparian, et al.
Lancet (London, England)|December 14, 2025
Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trialAlison Luckey, Manica Balasegaram, Lindley A Barbee, et al.
The Lancet Regional Health. Western Pacific|September 9, 2025
Antimicrobial resistance in <i>Neisseria gonorrhoeae</i> in nine sentinel countries within the World Health Organization Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP), 2023: a retrospective observational studyIsmael Maatouk, Phiona Vumbugwa, Thitima Cherdtrakulkiat, et al.
Annals of the New York Academy of Sciences|August 10, 2011
The evolution of infectious agents in relation to sex in animals and humans: brief discussions of some individual organismsDavid L Reed, Russell W Currier, Shelley F Walton, et al.
Antimicrobial Agents and Chemotherapy|July 8, 2010
Multicenter study for defining the breakpoint for rifampin resistance in Neisseria meningitidis by rpoB sequencingMuhamed-Kheir Taha, Sara Thulin Hedberg, Marek Szatanik, et al.
The Journal of Antimicrobial Chemotherapy|December 16, 2025
High in vitro activity of the novel antimicrobial gepotidacin against Neisseria gonorrhoeae isolates in eight WHO Enhanced Gonococcal Antimicrobial Surveillance Programme countries in three WHO regions, 2021-24Josefine Ahlstrand, Ismael Maatouk, Le Huu Doanh, et al.
Pageof 44